Objectives

After participating in this educational activity, attendees should be able to:

1| Review pathophysiology of T2DM
2|Identify current ADA recommendations for management of Type 2 Diabetes Mellitus and place in therapy for GL1-RA
3| Introduce and evaluate SURPASS-2 Trial
4| Consider place in therapy of Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like Peptide (GLP-1) Receptor Agonist
Faculty

Rachel Yan, PharmD
PGY1 Community Pharmacy Resident
Pharmacist
Baystate Medical Center 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

None of the other planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Session date: 
10/10/2022 - 2:00pm to 3:00pm EDT
Location: 
Webinar
Baystate Medical Center
759 Chestnut St
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.